Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 54OTHER 46NIH 2NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Newly Diagnosed Oligometastatic Prostate Cancer 1

Interventions

sargramostim 3Methods 3Granulocyte-Macrophage Colony-Stimulating Factor 3Exercise 3Colonoscopy 3Prednisone 2Palliative Care 2Leuprolide 2Golytely 2Gelatin 2Decision Support Techniques 2Collagenases 2Clofarabine 2Cholecalciferol 2Calcitriol 2ADI PEG20 2talabostat 1sulforaphane 1apalutamide 1abiraterone 1Yoga 1Water 1Tretinoin 1Topotecan 1Thioctic Acid 1Tablets 1Surgical Instruments 1Streptozocin 1Standard of Care 1Social Work 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × FED × Abiraterone Acetate × Clear all
NCT03298087 2025-08-01

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

VA Office of Research and Development

Phase 2 Completed
28 enrolled 10 charts
Genitourinary

Newly Diagnosed Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡